

**From: Aikaterini Mastoraki**

29 Irodotou street, Maroussi, Athens, Greece

Tel: +30-6932577710

Fax: +30-213-2061018

E-mail: dr\_kamast@yahoo.gr

**To: The Editorial Board**

**World Journal of Gastrointestinal Oncology**

Athens, 24 July 2018

Dear Editor

We have the pleasure to submit our revised manuscript entitled: "Facing the challenge of venous thromboembolism prevention in patients undergoing major abdominal surgical procedures for gastrointestinal cancer" to your distinguished journal for publication.

We would like to state the significance and uniqueness of this work in the authors view. We consider our work as an original clinical contribution not previously published or submitted in any other journal. All authors contributed significantly in all stages of this work, they have read and approved the revised manuscript and confirm that no conflict of interest exists.

We would also like to inform you that we took into thoughtful consideration all the reviewers' constructive suggestions. We are able to report the following revisions:

Answer to reviewer 1:

With regard to your proposal the differences between doses of dabigatran and apixaban and the correlations between the safety and timing differences between dabigatran or apixaban and rivaroxaban or edoxaban are summarized in Table 1. Additional sentence has been included in the text as you recommended.

Answer to reviewer 2:

- 1) In accordance with your constructive remark, in the text under "THERAPEUTIC APPROACH", the authors added a table to make them easy to understand the contents of action of drugs classified as NOACs.
- 2) In the text under "DIAGNOSTIC MODALITIES" have been added 2 tables with regard to DVT and PE detection to make them easy to understand.
- 3) According to your suggestion, the phrase "GI cancers are frequently treated with antiangiogenic agents, such as cisplatin and irinotecan, which are associated with increased risk for VTE as well as combined neoadjuvant chemotherapy" has been replaced by the sentence "GI cancers are frequently treated with antiangiogenic or chemotherapeutic agents, such as cisplatin and irinotecan, which are associated with increased risk for VTE as well as combined neoadjuvant chemotherapy". Relevant correction has been added in the Text under "THERAPEUTIC APPROACH".

- 4) Language corrections have been accomplished throughout the text as you commented.

Answer to reviewer 3: None.

Please do not hesitate to contact us (corresponding author: Aikaterini Mastoraki) if you need any further information. We are looking forward to your response.

Kindest regards

The authors:

Aikaterini Mastoraki, MD, PhD

Sotiria Mastoraki, MD, PhD

Dimitrios Schizas, MD, PhD

Raphael Patras, MD

Nikolaos Krinos, MD

Ioannis S Papanikolaou, MD, PhD, Assistant Professor of Internal Medicine

Andreas Lazaris, MD, PhD, Associate Professor of Vascular Surgery

Theodore Liakakos, MD, PhD, Professor of Surgery

Nikolaos Arkadopoulos, MD, PhD, Associate Professor of Surgery